期刊文献+

化学疗法对肿瘤的分子免疫调控研究

Immunomodulatory activity of cancer chemotherapy
原文传递
导出
摘要 除了直接的细胞毒作用,对荷瘤机体的免疫调节是化学疗法发挥作用的另一重要方面。清除调节性T细胞,骨髓来源的免疫抑制细胞和调节肿瘤细胞表面凋亡受体的表达,增加肿瘤细胞对免疫效应的应答能力是其相关的分子机制。化学疗法的作用新机制为临床合并免疫,中医药的治疗提供了新的实验依据。 In addition to kill tumor cells through direct cytotoxicity, the immunomodulatory activity is another facet of chemotherapy. The major molecular mechanisms of immunogenicity of eytotoxic drugs are elimination of CD4+ CD25+ regulatory T cells or Myeloid-Derived Suppressor Cells, and sensitization of tumor cells to immune effectors through modulation of death receptor expression. These studies provide scientific evidence for combinatorial treatments including vaccines and Traditional Chinese Medicine for cancer therapy.
出处 《肿瘤研究与临床》 CAS 2010年第1期70-72,共3页 Cancer Research and Clinic
基金 基金项目:国家科技部国际合作课题(2006DFA31700) 国家自然科学基金(30600839,30672764)
关键词 药物疗法 联合 免疫 分子作用机制 Drug therapy, combination Immunity Molecular mechanisms of action
  • 相关文献

参考文献31

  • 1Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Eng J Med, 1985, 312: 818-822.
  • 2Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler, 2002, 8: 142-154.
  • 3Cedric M, Franois M, Lionel A, et al. Cancer chemotherapy: not only a direct cytotoxic effect,but also an adjuvant for antitumor immunity. Cancer Immunol Immunother, 2008, 57: 1579-1587.
  • 4Barrett A J, Savani BN. Does chemotherapy modify the immune surveillance of hematological malignancies? Leukemia, 2009, 23: 53-58.
  • 5Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4^+ CD25^+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol, 2004, 34: 336-344.
  • 6Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4^+ CD25^+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother, 2007, 56: 641-648.
  • 7Ko H J, Kim Y J, Kim YS et al. A combinalion of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res, 2007, 67: 7477-7486.
  • 8North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor induced suppressor T cells. J Exp Med, 1982, 155:1063-1074.
  • 9翟晋芳(综述),韩福才(审校).CD4^+CD25^+调节性T细胞与肿瘤的相关性研究[J].肿瘤研究与临床,2009,21(3):205-207. 被引量:6
  • 10Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 1995, 155:1151-1164.

二级参考文献25

  • 1Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25. Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 1995, 155:1151-1164.
  • 2Vigouroux S, Yvon E, Biagi E, et al. Antigen-induced regula tory T cells. Blood, 2004, 104: 26-33.
  • 3Muller A J, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer, 2006, 6: 613-625.
  • 4Khazaie K, Von Boehmer H. The impact of CD: CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol, 2006, 16: 124-136.
  • 5Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD 4+ CD25+ regulatory T cells. Nat Immunol, 2003, 4: 330-336.
  • 6Kiniwa Y, Miyahara Y, Wang HY, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res, 2007.13: 6947-6958.
  • 7Paust S, Lu L, McCarty N, et al. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A, 2004, 101: 10398-10403.
  • 8Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol, 2004, 4: 762-774.
  • 9Maloy KJ, Salaun L, Cahill R, et al, CD4+ CD25+ Treg suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med, 2003, 197: 111-119.
  • 10Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor. J Exp Med, 2001, 194: 629-644.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部